

India **Pharma** *Outlook*

MAY, 2025
STARTUPS IN CELL AND GENE THERAPY

INDIAPHARMAOUTLOOK.COM



DR LEELA KRISHNA,
CEO

DR SUBHADRA DRAVIDA,
FOUNDER

TRANSCELL BIOSCIENCES

Transforming Healthcare through
Bio-Banking Excellence

₹150



Pharma *Outlook* TOP 10
**STARTUPS IN CELL
AND GENE THERAPY 2025**

TRANSCELL BIOSCIENCES

Transforming Healthcare
through Bio-Banking
Excellence



By Sudhakar Singh

The healthcare sector and biotechnology industry have experienced exceptional growth over the past decade. The growing market demand for personalized medicine has created a pressing need for innovative solutions to manage chronic diseases. On this path, the market faces significant barriers, including regulatory compliance issues, as well as high capital requirements and the need for advanced infrastructure support. The complexity of bio-banking ethics management, combined with advanced technological integration, creates additional rigour for emerging healthcare companies.

Transcell Biosciences has adopted advanced cell technology to become a trailblazer in developing transformative solutions that overcome current market obstacles. Its distinctive bio-banking solutions enable affordable and accessible medical treatments, helping to implement precision medicine in the Indian healthcare sector. Through its research, technology, and patient care connection platform, the company has established a pathway that brings scientific breakthroughs into practical healthcare applications.





Previously known as Transcell Biolife, the company has taken deliberate steps to capitalize on such opportunities by developing proprietary cell technology platforms in conjunction with innovative bio-banking solutions. Dr Subhadra Dravida, a visionary founder, established the company with a mission to utilize advanced cell technology for medical transformations, leveraging next-generation bio-banking practices throughout India. The company has implemented a strategy that merges groundbreaking research findings with practical applications, explicitly supporting clinicians practising regenerative medicine in the treatment of patients with chronic diseases, with Dr Leela Krishna as the CEO.

"Our state-of-the-art laboratories and unwavering commitment to strict global standards enable us to translate research breakthroughs into practical clinical applications, ensuring that patients benefit from personalized, effective treatments. This dedication has built strong trust among our clients, establishing us as a premier team in the stem cell technology field in India," asserts Dr Leela Krishna, CEO, Transcell Biosciences.

Overcoming Indigenous Stem Cell Storage Challenges

Transcell Biosciences initiated an endeavor to introduce India's domestically developed stem cell storage service to the market. The enterprise encountered regular startup hurdles since it required substantial capital to develop its infrastructure while teaming up with a skilled workforce in the field. The deep understanding and expertise it possessed of the domain, along with the nuances of fabricating GLP and GMP facilities, enabled it to build exact and compliant infrastructure. The company implemented lean methodologies and assembled specialized teams that maintained its focus throughout the ups and downs of the startup journey, ultimately achieving credibility within the competitive biotechnology industry.

The native and original technology development that the team has undertaken since its inception has reduced costs associated with expensive imports while creating affordable solutions at scale.

A Patient-Centric Approach to Innovation

The core intellectual property of the company serves as the fundamental basis for efforts to convert laboratory discoveries into application-based solutions. The company is dedicated to developing practical solutions that have a positive impact on patient care. The initiative to understand patient needs, combined with treatment customization, allows Transcell Biosciences to maintain person-centred

care within a field dominated by technology and scientific research. The company's focus on hematopoietic stem cell transplant procedures permits it to deliver customized medical solutions for people with blood cancer treatment needs.



Our state-of-the-art laboratories and unwavering commitment to strict global standards enable us to translate research breakthroughs into practical clinical applications, ensuring that patients benefit from personalized, effective treatments

The Bioactive Regenerative Tooth Implant (BARTI), developed by the company, offers periodontists an innovative tool for conducting more effective clinical research using preserved pulp cells. Through its partnerships and working relationships with leading research institutions and hospitals, the firm stays updated with scientific discoveries, which enables it to continue offering breakthrough, transformative solutions.


Regulatory and Ethical Compliance

Transcell Biosciences operates within a mature regulatory framework for bio-banking and personalized medicine, ensuring compliance with licensing protocols and standard operating procedures. The company's expertise and long-standing experience allow it to meet existing standards and contribute to strengthening the ecosystem that supports excellence in patient care and compliance with legal guidelines regarding the use of biological samples and patient information. The team focuses on innovation while adhering to regulations and building trust with regulators and stakeholders. This approach ensures them to innovate responsibly, protect patient rights, and improve transparency and credibility.

Strategic Partnerships & Global Reach

The company plans to establish partnerships with various cancer care centres across India, with the intention of

expanding into Asia, the UAE, and Africa. The goal is to personalize stem cell transplantation and management for families with a history of cancer, offering services that include genetic predisposition profiling before the implementation of specialized treatments. Furthermore, there is an objective to collaborate with pharmaceutical companies in India to develop innovative and affordable cancer treatments. The company also aims to partner with periodontists in India to provide pulp cells from a biobank and support the use of cell technology for personalized treatments of periodontal diseases. Additionally, they seek to collaborate with plasma fractionation companies in India by supplying new additives intended to enhance their output and reduce reliance on imports.



Future Vision and Leadership

The vision of the company is to establish itself as a highly valued bio-bank that plays a crucial role in delivering innovative treatments and cure options for chronic diseases. They are committed to harnessing cutting-edge cell technology and foundational expertise to create transformative medical solutions that address the urgent healthcare needs of patients in India. By focusing on the development of personalized medicine and leveraging population-level clinical informatics, the passionate team aims to unlock new pathways for affordable treatments, thereby improving patient outcomes and enhancing the quality of life for those who require medical attention. With Uday Chatterjee of Indian Angel Network mentoring the team, they harmoniously align with the values of their investors and stakeholders, including clients, fostering a future full of potential. **PO**